Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?
BMJ Oncology · 2026-01 · 5 (1) · e001024
DOI: 10.1136/bmjonc-2025-001024 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ Oncology, online erschienen am 02.04.2026. Verfasst von Oscar Corli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives To evaluate sex differences in baseline clinical characteristics, analgesic response, safety profiles and treatment variations among cancer patients initiating WHO step III opioid therapy. Methods and analysis This post hoc analysis used data from a four-arm, multicentre, randomised, comparative, superiority phase IV trial in cancer patients with moderate-to-severe pain requiring WHO step III opioids. The study was conducted across 44 specialist palliative care centres in Italy. Overall, 498 patients were evaluated, including 277 men (55.6%) and 221 women (44.4%). Eligible participants had locally advanced or metastatic tumours and persistent moderate-to-severe pain. Patients were centrally randomised (1:1:1:1) to morphine, oxycodone, buprenorphine or fentanyl around the clock. Follow-up lasted 28 days, with assessments on days 1 day, 3 days, 7 days, 14 days, 21 days and 28 days. Physicians could adjust opioid doses, add adjuvants or switch opioids as clinically indicated. Adverse drug reactions (ADRs) were recorded. Baseline assessments included oncological history, comorbidities, Karnofsky performance status and self-reported psychological status. Pain intensity (PI) was measured on a 0–10 Numerical Rating Scale for average PI (API) and worst pain over the previous 24 hours at each visit. Analgesic response was classified per Farrar’s criteria as non-responders (no improvement or worsening), poor responders (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, Istituto Di Ricerche Farmacologiche Mario Negri, Milan, Italy.
- Presidence, Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy.
- Scientific Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
- Organization of European Cancer Institutes, Brussels, Belgium.
ORCID-Profile: Lorenzo Caldirola
Zitieren
APA
Corli, O., Caldirola, L., Galli, F., Torri, V., Garattini, S., Rulli, E., & Apolone, G. (2026). Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?. BMJ Oncology, 5(1), e001024. https://doi.org/10.1136/bmjonc-2025-001024
Vancouver
Corli O, Caldirola L, Galli F, Torri V, Garattini S, Rulli E, et al. Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?. BMJ Oncology. 2026;5(1):e001024. doi:10.1136/bmjonc-2025-001024
BibTeX
@article{Corli2026,
author = {Corli, Oscar and Caldirola, Lorenzo and Galli, Francesca and Torri, Valter and Garattini, Silvio and Rulli, Eliana and Apolone, Giovanni},
title = {Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?},
journal = {BMJ Oncology},
year = {2026},
volume = {5},
number = {1},
pages = {e001024},
doi = {10.1136/bmjonc-2025-001024}
}
EUVIMED